Update shared on 16 Dec 2025
Analysts have maintained their 12 month price target for Acutaas Chemicals at $1,831.50, reflecting stable assumptions around revenue growth, profit margins, and future valuation multiples that continue to support the companys current fair value assessment.
What's in the News
- A board meeting is scheduled for October 17, 2025, at 11:00 Indian Standard Time to review and approve the unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2025 (company filing).
Valuation Changes
- Fair Value: Unchanged at ₹1,831.50 per share, indicating no revision to the 12 month target valuation.
- Discount Rate: Stable at 12.76 percent, suggesting no reassessment of the company’s risk profile or cost of capital.
- Revenue Growth: Effectively unchanged at about 33.16 percent, with only an immaterial numerical refinement in the model.
- Net Profit Margin: Steady at about 23.44 percent, reflecting no material change in margin expectations.
- Future P/E: Maintained at approximately 38.93x, signaling consistent assumptions for the company’s forward earnings multiple.
Have other thoughts on Acutaas Chemicals?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.